Xenetic Biosciences
XBIO
8 hedge funds and large institutions have $581K invested in Xenetic Biosciences in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
14% more funds holding
Funds holding: 7 → 8 (+1)
1.13% more ownership
Funds ownership: 7.52% → 8.65% (+1.1%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
21% less capital invested
Capital invested by funds: $736K → $581K (-$155K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.45M |
| 2 |
VF
Virtu Financial
New York
|
+$125K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$60.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.29K |
| 5 |
CA
Crewe Advisors
Salt Lake City,
Utah
|
+$429 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$128K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$4K |
XBIO Hedge Fund Activity: Q3 2019 in Review
8 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q3 2019, worth a combined $581K — down 21% from $736K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new XBIO positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.45M. The largest seller was Morgan Stanley, cutting an estimated $128K.
- 8 institutional investors held Xenetic Biosciences (XBIO) as of Q3 2019, up from 7 in Q2 2019.
- Funds reported $581K of Xenetic Biosciences stock for Q3 2019, down 21% quarter-over-quarter.
- 4 funds opened new Xenetic Biosciences positions in Q3 2019 and 3 closed out, a net change of +1 holder.
- The largest Xenetic Biosciences buyer in Q3 2019 was Sabby Management, an estimated $1.45M added.
- The largest Xenetic Biosciences seller in Q3 2019 was Morgan Stanley, an estimated $128K sold.
Based on aggregated 13F filings for Q3 2019.